^
CANCER:

Multiple Myeloma





Show legend
Group by Gene:
Include preclinical:

Proteasome inhibitor
0
Proteasome inhibitor
bortezomib
carfilzomib
ixazomib
daratumumab
daratumumab / hyaluronidase
isatuximab-irfc
1
CD38 inhibitor
BHV-1100
TAK-079
SAR442085
isatuximab-irfc + K-NK004
BCMA-targeted CAR-T immunotherapy
ciltacabtagene autoleucel
idecabtagene vicleucel
ALLO-605
2
BCMA-targeted CAR-T immunotherapy
PBCAR269A
ALLO-715
equecabtagene autoleucel
CB-011
bb21217
ACLX-001
melphalan flufenamide
3
Alkylating agent
melphalan
cyclophosphamide
elranatamab-bcmm
4
CD3 agonist, BCMA inhibitor
teclistamab
HPN-217
AMG 701
Bcl2 inhibitor
venetoclax
5
Bcl2 inhibitor
venetoclax
BGB-11417
APG-2575
6
TNF inhibitor
thalidomide
7
XPO1 inhibitor
selinexor
8
HDAC inhibitor
panobinostat
9
GCR agonist
dexamethasone tablets
10
Bone resorption factor inhibitor, Osteoclast inhibitor
zoledronic acid
11
DNA replication inhibitor
bendamustine
12
CD38 inhibitor, TNF inhibitor
daratumumab + thalidomide
thalidomide + daratumumab / hyaluronidase
13
CD3 agonist, GPRC5D inhibitor
talquetamab-tgvs
14
RANK ligand inhibitor
denosumab
15
CD38 inhibitor, XPO1 inhibitor
selinexor + daratumumab
16
NK cell stimulant
IDP-023
17
Wilms tumor 1 inhibitor
galinpepimut-S
18
CBP inhibitor, EP300 inhibitor
CCS1477
19
MEK inhibitor, BRAF inhibitor
BRAF inhibitor + MEK inhibitor
trametinib + dabrafenib
20
KIF11 inhibitor
ARRY-520
21
CRL4-CRBN E3 ubiquitin ligase modulator
CC-220
22
BRAF inhibitor, BRAF V600E inhibitor
vemurafenib
23
Bcr-abl tyrosine kinase inhibitor
nilotinib
24
MDM2 inhibitor
KRT-232
APG-115
25
Proteasome inhibitor, Immunomodulator
Proteasome inhibitor + Immunomodulator
VTD
D-VTd
RD
VMP
VRD
PVD
EloRd
IRd
KRd
DRd
DVMP
CyBorD
EloPd
26
Chemotherapy
Isa-PD
VenVd
DVD
IsaKd
DKd
DCEP
BVD
BRD
D-KRd
KD
VD
TD
Isa-KRd
SVd
RAD
27
BRAF inhibitor
BRAF inhibitor
28
Immunomodulator
Immunomodulator
29
MEK inhibitor
MEK inhibitor
trametinib
30
T-lymphocyte cell therapy
T-lymphocyte cell therapy
31
ALK inhibitor
ALK inhibitor
32
DOT1L inhibitor
DOT1L inhibitor
33
TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor
lenalidomide
34
TNFα inhibitor, IL-12 inhibitor, CS-1 inhibitor, IL-6 inhibitor
lenalidomide + elotuzumab
lenalidomide + ixazomib
35
TNFα inhibitor, IL-12 inhibitor, Proteasome inhibitor, IL-6 inhibitor
lenalidomide + bortezomib
lenalidomide + carfilzomib
36
BCMA-targeted antibody-drug conjugate, Microtubule inhibitor
belantamab mafodotin-blmf
pomalidomide + isatuximab-irfc
37
TNFα inhibitor, CD38 inhibitor, IL-1β inhibitor, IL-10 stimulant, NK cell stimulant, IL-6 inhibitor
pomalidomide + daratumumab / hyaluronidase
daratumumab + pomalidomide
lenalidomide + isatuximab-irfc
38
TNFα inhibitor, CD38 inhibitor, IL-12 inhibitor, IL-6 inhibitor
lenalidomide + daratumumab
lenalidomide + daratumumab / hyaluronidase
39
TNFα inhibitor, IL-1β inhibitor, IL-10 stimulant, NK cell stimulant, IL-6 inhibitor
pomalidomide
40
XPO1 inhibitor, Proteasome inhibitor
selinexor + carfilzomib
bortezomib + selinexor
41
TNFα inhibitor, IL-1β inhibitor, Proteasome inhibitor, IL-10 stimulant, NK cell stimulant, IL-6 inhibitor
ixazomib + pomalidomide
carfilzomib + pomalidomide
42
TNFα inhibitor, XPO1 inhibitor, IL-1β inhibitor, IL-10 stimulant, NK cell stimulant, IL-6 inhibitor
selinexor + pomalidomide
43
Proteasome inhibitor, CS-1 inhibitor
bortezomib + elotuzumab
44
Alkylating agent, TNF inhibitor
thalidomide + melphalan
45
Alkylating agent, DNA synthesis inhibitor
carmustine
46
HDAC inhibitor, Proteasome inhibitor
bortezomib + panobinostat
47
TNFα inhibitor, IL-1β inhibitor, CS-1 inhibitor, IL-10 stimulant, NK cell stimulant, IL-6 inhibitor
pomalidomide + elotuzumab
48
Topoisomerase II inhibitor, Proteasome inhibitor
bortezomib + pegylated liposomal doxorubicin
49
MEK1 inhibitor, Bcl2 inhibitor
venetoclax + cobimetinib
50
Proteasome inhibitor, Bcl2 inhibitor
venetoclax + bortezomib
venetoclax + bortezomib
51
CD56-targeted antibody-drug conjugate, Microtubule inhibitor
IMGN901
52
CD38 inhibitor, Bcl2 inhibitor
venetoclax + daratumumab
53
TNFα inhibitor, CD38 inhibitor, IL-1β inhibitor, MEK inhibitor, IL-10 stimulant, NK cell stimulant, IL-6 inhibitor
trametinib + daratumumab + pomalidomide
54
PD-L1 inhibitor, MEK1 inhibitor, Bcl2 inhibitor
venetoclax + atezolizumab + cobimetinib
55
XPO1 inhibitor, Bcl2 inhibitor
venetoclax + selinexor
56
BRAF inhibitor, MEK1 inhibitor, BRAF V600E inhibitor
vemurafenib + cobimetinib
57
cRAF inhibitor, MEK inhibitor, BRAF inhibitor
binimetinib + encorafenib
58
Protease inhibitor, Proteasome inhibitor, AKT inhibitor
bortezomib + nelfinavir
59
Proteasome inhibitor, Bcl-xL inhibitor
bortezomib + A-1331852
60
BRD3 inhibitor, BRD4 inhibitor, BRD2 inhibitor
I-BET151
61
Proteasome inhibitor, Protein homeostatic modulator
bortezomib + BTX306
62
CD38 inhibitor, CD3 agonist, CD28 agonist
SAR442257
63
ATR inhibitor
VE-821
64
KRAS inhibitor
AZD4785
MRTX1257
65
BCMA inhibitor, NK cell stimulant, CD16A agonist
CTX-8573
66
USP47 inhibitor
P5091
67
MCL1 inhibitor
APG-3526
S63845
68
CD38-targeted antibody-drug conjugate, Microtubule inhibitor
STI-6129
69
TNFα inhibitor, IL-12 inhibitor, CBP inhibitor, IL-6 inhibitor, EP300 inhibitor
lenalidomide + CCS1477
70
ATR inhibitor, RNA polymerase 1 inhibitor
CX-5461 + VE-821
71
MYC inhibitor
GT19077
72
TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor, Bcl2 inhibitor
lenalidomide + APG-2575
73
CD19-targeted CAR-T immunotherapy
ATA3219
74
HDAC inhibitor, PI3K inhibitor
CUDC-907
75
AKT inhibitor
TAS-117
futibatinib
76
FGFR inhibitor
ABSK091
AZ8010
infigratinib
77
JAK1 inhibitor, JAK2 inhibitor
ruxolitinib
78
Tyrosine kinase inhibitor
PD173074
79
Multi-tyrosine kinase inhibitor
midostaurin
gilteritinib
80
HDAC11 inhibitor
JB3-22
81
TNFα inhibitor, IL-12 inhibitor, DNA methylation inhibitor, IL-6 inhibitor
lenalidomide + azacitidine
82
κ myeloma antigen inhibitor, NK cell stimulant
KappaMab
83
SMARCA4 inhibitor, SMARCA2 inhibitor
PFI-3
84
CS-1 inhibitor
elotuzumab
85
eIF2α dephosphorylation inhibitor
salubrinal
86
CD38 inhibitor, CD3 agonist
ISB 1342
87
CD20 inhibitor
obinutuzumab
88
BET inhibitor, MYC inhibitor
JQ-1 + 10058-F4
89
ICAM-1-targeted CAR-T immunotherapy
AIC100
90
MEK inhibitor, Bcl2 inhibitor
venetoclax + trametinib
91
Proteasome inhibitor, MDM2 inhibitor
bortezomib + APG-115
92
AMPK activator, MCT1 inhibitor, MCT4 inhibitor
metformin + syrosingopine
93
Menin-MLL inhibitor
BMF-219
94
CD38 inhibitor, CD47 inhibitor
ABBV-IMAB-TJC4 + MOR202
95
CD3 agonist, CRL4-CRBN E3 ubiquitin ligase modulator, BCMA inhibitor
CC-93269 + CC-220
96
Cereblon modulator, CD3 agonist, BCMA inhibitor
CC-93269 + CC-92480
97
Topoisomerase II inhibitor
epirubicin
doxorubicin hydrochloride
98
MERTK inhibitor
RGX-019
99
CD38-targeted antibody-drug conjugate, Ionizing radiation emitter
Actinium-225 conjugated to daratumumab
100
TROP-2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
OBI-992
101
MERTK-targeted antibody-drug conjugate, Microtubule inhibitor
RGX-019-MMAE
102
SLC1A5-targeted antibody-drug conjugate, DNA replication inhibitor
MEDI7247
103
GPRC5D-targeted antibody-drug conjugate, Microtubule inhibitor
AZD0305
104
BCMA-targeted antibody-drug conjugate, RNA polymerase 2 inhibitor
HDP-101
105
CD38 inhibitor, Protein synthesis inhibitor
MT-0169
106
CD352-targeted antibody-drug conjugate, DNA replication inhibitor
SGN-CD352A
107
CD48-targeted antibody-drug conjugate, Microtubule inhibitor
SGN-CD48A
108
Autophagy inhibitor, ULK3 inhibitor
MA9060
109
CD3 agonist, BCMA inhibitor, GPRC5D inhibitor
JNJ-5322
110
KRAS G12D inhibitor
MRTX1133
111
DNA synthesis inhibitor
cisplatin
112
MEK inhibitor, PI3K inhibitor, mTOR inhibitor
CI-1040 + PI-103
113
BET inhibitor
JQ-1
No biomarker
TNFRSF17 expression
BRAF V600E
BRAF mutation
TNFRSF17 deletion
Chr t(11;14) + BRAF mutation
TNFRSF17-L
BRAF V600
TNFRSF17 overexpression
TNFRSF17 underexpression
TNFRSF17 positive
TNFRSF17 amplification
TNFRSF17 elevation + Chr t(14;16)
CD38 expression
CRBN expression
CD38 positive
CRBN underexpression
CD38 overexpression
CRBN rs1714327G > C
CRBN rs1705814T > C
CRBN R283K
CRBN overexpression
CRBN Q99
BCL2 overexpression
RPL5 expression
KRAS mutation
TP53 mutation
Chr t(11;14) + TP53 mutation
TP53 wild-type
Chr t(11;14) + KRAS mutation
BCL2 expression
BCL2 mutation
Chr t(11;14) + BCL2 overexpression
KRAS G12C
BCL2 underexpression
KRAS G12D
KRAS G12A
CUL4A expression
CUL4A overexpression
NRAS mutation
BCL2/BCL2L1 ratio elevation
Chr t(11;14) + NRAS mutation
HLA-DQB1*03:02
HLA-DQB1*05:01
Chr t(11;14) + BCL2 : BCL2L1 ratio elevation
NRAS Q61K
NRAS G13D
NRAS Q61H
NRAS G12V
NRAS G13N
LPXN expression
GPR176 expression
TK1 expression
IL7R overexpression
PTBP1 underexpression
HLA-DRB1*01:01
MAFB overexpression
CD27 expression
CCND1 overexpression
IL4 elevation
IL13 elevation
MAGEC1 expression
miR-16 underexpression
BCL2 overexpression + CCND1 overexpression
TFG-ALK fusion
NRF1 expression
MYD88 L265P
IL17C-L
CCL3-L
XPNPEP1 overexpression
IL6-L
LDH elevation
BCL2/MCL1 ratio elevation
TMPRSS11E expression
STRA6 expression
CLEC7A expression
NFKB2 negative
NF1 mutation
DDB1 overexpression
NCAM1 positive
PTPRC expression
CD200 expression
NRF1 overexpression
CCND1 expression
Chr t(11;14)
Chr del(17)(p13)
Chr amplification(1)(q21)
Chr t(4;14)
Chr del(17p)
Chr t(14;16)
7-gene signature
Chr t(14;20)
RAS mutation
6-gene signature
Chr t(4;9;22)(q21;q34;q11)
Chr del(5q)
FGFR2 mutation
MYC expression
ETV6-FGFR3 fusion
FGFR3 K650
FGFR3 V555M
TNFRSF17 expression + GPRC5D expression
POMP overexpression
RAB22A underexpression
GABARAP deletion
ENSG00000273062 underexpression
MCL1 underexpression
MYCL overexpression
CRBN elevation + SPARC-L
BCL2L1 underexpression
SDC1 positive
SPARC-L + IKZF3 elevation
Chr amplification(1q)
TRIP13 mutation + MYC mutation
BIRC3 deletion
TMC2 deletion
IRF4 expression
HNRNPK overexpression
MYC overexpression
EEF1A1 overexpression
miR-33 underexpression
EZH2 deletion
FGFR3 Y373C
CD276 overexpression
MCL1 expression
H2BC8 underexpression
Chr del(13q)
BMI1 expression
TENT5C mutation
CD20 underexpression
BCL7A mutation
CEP290 mutation
DPP3 overexpression
RNPEP overexpression
BLMH overexpression
PPP1R15B overexpression
GPRC5D overexpression
MAF overexpression
CCL20 underexpression
WWP2 underexpression
ICAM1 overexpression
BCL2L1 overexpression
MCL1 overexpression
CDK6 overexpression
S100A9 expression
B2M-HLA-E fusion
MCT1 overexpression + SLC16A3 overexpression
CD47 overexpression + CD38 underexpression
CD47 overexpression
TP73 overexpression
MERTK expression
BNIP3 overexpression
SLC1A5 overexpression
SLC1A5 expression
S100A8 expression
SLAMF6 expression
CD48 overexpression
GPRC5D expression
Chr del(11q)
B2M elevation
miR-92b-5p expression
PSMC2 overexpression
PSMC6 overexpression
FADD underexpression + BID underexpression
Chr t(11;14) + Chr amplification(1q)
CRIP1 overexpression
NEK2 overexpression + Chr t(4;14)
C1As
PSMD10 overexpression
IRF4 underexpression
PSMD1 overexpression
PSMD4 overexpression
IKZF1 overexpression
AGO2 overexpression
IKZF3 overexpression
Chr t(11;14)(q13;q32)
DOT1L overexpression
HDAC11 underexpression
HDAC11 overexpression
ABCB1 overexpression
PMAIP1 underexpression
BCL2L11 underexpression
FGFR3 K650E
CD19 expression
MCT1 overexpression
MYC translocation
IGH translocation
TOP2A overexpression
OTUD6B expression + MYC expression
SDC1 elevation
SPN positive
FLT3 overexpression